The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Insights into the ENHANCE-3 study: azacitidine plus venetoclax with or without magrolimab in AML
Guru Subramanian Guru Murthy, MD, Medical College of Wisconsin, Milwaukee, WI, discusses the Phase III ENHANCE-3 study (NCT05079230), which investigated azacitidine and venetoclax with or without magrolimab, a CD47-targeting antibody, in patients with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive chemotherapy. Despite high expectations, the study did not meet its primary endpoint of overall survival (OS) and noted increased risk of adverse events in the treatment arm. Despite these results, this trial provides valuable insights into the use of immunotherapy in AML. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
